title: [Serologic monitoring of patients with endometrial carcinoma using ovarian carcinoma antigen (CA 125)].
abstract: The serum concentrations of CA 125 were determined in 136 corpus carcinoma patients. Before the primary irradiation therapy in 40.2% (19/47), after the hysterectomy 3.4% (3/89) of the patients had elevated (> 35 U/ml) CA 125 levels. CA 125 values above the normal range were frequently associated with advanced stages. Measuring elevated levels after hysterectomy proved bad prognosis. There were no correlation of CA 125 levels and degree of the histological type and differentiation of the tumor. Serological follow up revealed a correlation with the clinical course of the endometrial carcinoma in 62% (31/50). 18 cases who had tumor progression associated rising CA 125 levels. In 10 patients with tumor progression the CA 125 levels increased before clinical sign of progression with a median lead time of one month. The determination of CA 125 is recommended to check the endometrial carcinoma patients and to detect progression of the tumor.
authors.affiliation: Pécsi Orvostudományi Egyetem, Szülészeti, Nögyógyászati Klinika.
authors.forename: P
authors.initials: P
authors.lastname: Göcze
authors.forename: H
authors.initials: H
authors.lastname: Varhson
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology*; D002272:Carcinoembryonic Antigen / Q000276:immunology; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015166:Monitoring, Immunologic; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy
chemical_list: D000951:Antigens, Neoplasm; D002272:Carcinoembryonic Antigen; C017589:ovarian tumor associated antigen